Brief: UK's MHRA Says Elafibranor Approved As First Medicine To Treat Adults With A Rare Liver Disease Known As Primary Biliary Cholangitis
08/10/2024 11:47
Oct 8 (Reuters) - UK's MHRA:
* UK'S MHRA: ELAFIBRANOR APPROVED AS FIRST MEDICINE TO TREAT
ADULTS WITH A RARE LIVER DISEASE KNOWN AS PRIMARY BILIARY
CHOLANGITIS
Further company coverage: IPN.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ipsen SA
See all newsFulcrum falls after discontinuing sickle cell drug program
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics falls after scrapping sickle cell drug development
Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients